AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01520207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment
Study NCT01684514 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Confocal laser endomicroscopy
Description: Within recent years a new approach was introduced, wherein the microscopic structures of the intestinal mucous can be evaluated continuously in vivo during the endoscopic procedure. The technique is called confocal laser endomicroscopy (CLE). CLE functions by means of a laser device, which is inserted or build into an endoscope, and used as an illuminator of the lining of a small area and at a precise depth. The tissue is first added with fluorescence by intravenous administration. The reflection of the mucosa is captured in a focused area and magnified by which a two-dimensional image of mucosal microscopic structures is formed. This provides us with an optical biopsy, which can be compared with a similar microscopic image.
Study NCT01684514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy
Description: Within recent years a new approach was introduced, wherein the microscopic structures of the intestinal mucous can be evaluated continuously in vivo during the endoscopic procedure. The technique is called confocal laser endomicroscopy (CLE). CLE functions by means of a laser device, which is inserted or build into an endoscope, and used as an illuminator of the lining of a small area and at a precise depth. The tissue is first added with fluorescence by intravenous administration. The reflection of the mucosa is captured in a focused area and magnified by which a two-dimensional image of mucosal microscopic structures is formed. This provides us with an optical biopsy, which can be compared with a similar microscopic image.
Study NCT04330144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine as post exposure prophylaxis
Description: 1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po
Study NCT04330144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Others(No intervention)
Description: No treatment. Close monitoring and quarantine.
Study NCT01815658 — intervention group
Intervention type: DEVICE
Intervention: Carbon fiber intramedullary nail (PEEK-CF)
Description: Carbon fiber polyether-ether-ketone (PEEK-CF) PICCOLE Nail - produced by Carbofix, Herzlyia, Israel.
Study NCT04245917 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional natural history study
Study NCT00631982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro matuartion of oocytes
Description: in vitro maturation of (immature) oocytes
Study NCT04552561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My MS Toolkit
Description: My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
Study NCT04033978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Description: 10 sessions dealing with emotion recognition, jumping to conclusion, attributional style.program lasts 10 weeks
Study NCT04033978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial rehabilitation
Description: 10 sessions dealing psychosocial rehabilitation, neuropsychological evaluation, stigmatization, recovery process and severe mental disorders in general.
Study NCT02991248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: robotic training
Description: robotic training by applying pelvis force perturbation
Study NCT02991248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic training
Description: robotic training by applying pelvis force perturbation
Study NCT02991248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal cord electrical stimulation
Description: Applying direct current electrical stimulation on spinal cord
Study NCT02991248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treadmill
Description: conventional treadmill training only
Study NCT02991248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Description: conventional treadmill training only
Study NCT02991248 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: treadmill
Description: conventional treadmill training only
Study NCT01403558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioral therapy
Study NCT00874913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: measurement of ocular blood flow
Description: measurement of ocular blood flow with a laser Doppler flowmeter
Study NCT00871624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
Study NCT00871624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
Study NCT01156688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: sublingual 800mcg misoprostol 48 hours after oral 200mg mifepristone
Study NCT01913834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forsteo
Description: Subcutaneous administration 20 micrograms
Study NCT01913834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP046 PTH CriticalSorb
Description: Comparison of different doses of drug and nasal delivery devices
Study NCT04109781 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microscope assisted discectomy
Description: Microdiscectomy
Study NCT01156688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: buccal misoprostol 800mcg 48 hours after oral 200mg mifepristone
Study NCT01999647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraneural Injection for Subgluteal Sciatic Nerve Block
Description: The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach.
Study NCT01999647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineural Injection for Subgluteal Sciatic Nerve Block
Description: The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach.
Study NCT01999647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
Study NCT01999647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
Study NCT01999647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Postoperative Analgesia
Description: Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
Study NCT04419376 — intervention group
Intervention type: DEVICE
Intervention: driving pressure
Description: Mechanically ventilated patients (via ETT or trachestomy) were recorded for patients whose ventilation duration lasted at least 24 hours.We divided the patients into two groups by calculating the oxygenation index (OI): \[mean airway pressure(MAP) × fraction of inspired oxygen (FiO2) \]/ partial pressure of oxygen in arterial blood (PaO2) × 100) used in the classification of PALICC, including pARDS and non-pARDS.
Study NCT00599573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Ondansetron 4mg BID for six weeks
Study NCT03877861 — intervention group
Intervention type: DEVICE
Intervention: Readiband Sleep Tracking
Description: Once a patient has consented to study progression, a Readiband™ Sleep Tracker device will be provided to the patient, along with necessary instructions. Patients will return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits. In addition, surveys related to fatigue and quality of life will be administered via secure electronic survey to participants.
Study NCT02205034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: Intranasal administration
Study NCT01606410 — intervention group
Intervention type: OTHER
Intervention: IPC
Description: repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)
Study NCT01999647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Controlled Postoperative Analgesia
Description: Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
Study NCT01999647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Thirty milliliters of 0.75% (wt/vol) ropivacaine will be used for the sciatic nerve block.
Study NCT01999647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Thirty milliliters of 0.75% (wt/vol) ropivacaine will be used for the sciatic nerve block.
Study NCT00522548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric coated mycophenolate sodium
Description: Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
Study NCT00522548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent formulation manufactured by Sandoz, in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
Study NCT01507116 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Three separate survey questionnaires, one for each of the three diabetes groups. Each questionnaire is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions and rating scales.
Study NCT04750018 — intervention group
Intervention type: OTHER
Intervention: surgery
Description: Patients were divided into surgery and no disease.
Study NCT00478270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bondronat]
Description: 6mg iv on days 1-3
Study NCT00493012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D
Description: 6 drops of a vitamin D containing oil
Study NCT00493012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: 6 drops of a vitamin D containing oil
Study NCT01105104 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MedMinder System
Description: Participants will receive a fully activated reminder unit as well as at least one call per month from a counselor.
Study NCT01105104 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MedMinder System - deactivated
Description: Participants will receive a one-way reminder unit that will remotely transit information on medication adherence
Study NCT00193414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2 IV over 10 min, Day 1, prior to gemcitabine
Study NCT00193414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1500mg/m2, 30min IV
Study NCT03069235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family member / peer support
Description: supplemental individualized counselling
Study NCT03069235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced intervention with counselor support
Description: hands on EBF demonstrations
Study NCT03069235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: one on one and in-group counselling
Study NCT04244617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT with addition of peer-support
Description: Peer-supporters and participants, as well as psychologists and participants, interact in the treatment program via asynchronous secure messages. Peer-supporters are able to give support and feedback on exercises. A reconciliation call via telephone is entered into the middle of the treatment and a follow-up call after completion of treatment conducted by the peer-support. The interaction between peer-supporters and participants is tracked by the psychologist.
Study NCT04214574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasagittal oblique technique (Ultrasound)
Description: the probe will be placed in a parasagittal plane to identify the articular processes then the sacrum will be identified. The probe will be moved cephalad in the parasagittal axis until the identification of the target lumbar interspaces L2-L3, L3-L4 or L4-L5. Once the appropriate lumbar interspace is identified, the probe will be tilted 45 degree towards the midline into a parasagittal oblique view. The needle will be inserted in plane from the caudal end of the ultrasound transducer with its tip directed towards the interlaminar space under real-time in-plane US guidance.
Study NCT04214574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paramedian tranverse technique (Ultrasound)
Description: the transducer will be applied in the parasagittal plane, and after identification of the intervertebral level, the probe will be rotated 90 degrees into a transverse orientation and centered on the neuraxial midline in a way to align the beam with the interspinous and interlaminar space and thus to get a paramedian transverse interlaminar view. The needle will be inserted in plane from the lateral end of the ultrasound transducer with its tip directed towards the medial border of the articular process.
Study NCT00849069 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2231395A
Description: 3 doses intramuscular injections
Study NCT00849069 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TwinrixTM
Description: 3 doses intramuscular injections
Study NCT00541567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ibipinabant
Description: oral, tablet, once daily
Study NCT00541567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibipinabant
Description: oral, tablet, once daily
Study NCT00666211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Participants will be educated on pain management.
Study NCT00666211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Participants will be educated on pain management.
Study NCT00666211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titrated pain management
Description: Pain will be Monitored and Medication Titrated
Study NCT00666211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Participants will be given questionnaires to complete.
Study NCT00666211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Participants will be given questionnaires to complete.
Study NCT00577772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xifaxan
Description: Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients.
Study NCT00577772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPill
Description: The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (SmartPill) GI Monitoring System includes an ingestible capsule, a receiver and video display software.
Study NCT00577772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose hydrogen breath test (H_2BT)
Description: A hydrogen breath test provides information about the digestion of certain sugars or carbohydrates, such as milk sugar (lactose) or fruit sugar (fructose). The test is also used for detecting abnormal growth of bacteria within the small bowel by having the patient ingest lactulose.
Study NCT02198729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Submucosal Dissection
Study NCT02198729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Mucosal Resection
Study NCT00975377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hair clipping
Description: Patients randomized to the hair clipping cohort will be clipped using an Allegiance 4413 hair clipper. Hair removal will occur on the day of surgery by one of the preoperative nursing staff, immediately prior to the scheduled operation.
Study NCT04257396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon-Fibre Adjustable Reuseable Accessory (CARA)
Description: Breast support device having a carbon-fibre breast cradle for supine patient positioning.
Study NCT04164368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide combined with R-CHOP
Description: rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Lenalidomide 25mg PO QD D2-11
Study NCT00003483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with a meningioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study NCT01722370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Study NCT01722370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical air equivalent
Study NCT01245374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Norditropin NordiFlex®
Description: Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice
Study NCT03487965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose Polyphenol
Description: botanical supplement with 25 mg polyphenol
Study NCT03487965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose Polyphenol
Description: botanical supplement with 13 mg polyphenol
Study NCT03487965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: inert tablet made to mimic the experimental tablets
Study NCT02307045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
Study NCT02307045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine
Description: Nicotine replacement therapy with transdermal patches and/or chewing gums
Study NCT01509547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: participants >55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
Study NCT01509547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: participants >55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
Study NCT01935752 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: blood samples
Study NCT01935752 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vascular echotracking
Description: endothelial function study and virtual histology study
Study NCT02206061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-Based Asthma Care for Teens (SB-ACT)
Study NCT02206061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Directly Observed Therapy
Study NCT02206061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Education
Study NCT01747551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Study NCT01747551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Study NCT01747551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Study NCT01747551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziv-aflibercept